Oxygen-Dependent Ubiquitination and Degradation of Hypoxia-Inducible Factor Requires Nuclear-Cytoplasmic Trafficking of the von Hippel-Lindau Tumor Suppressor Protein

REFERENCES

• Berra, E., D. E. Richard, E. Gothie, and J. Pouyssegur. 2001. HIF-1-dependent transcriptional activity is required for oxygen-mediated HIF-1α degradation. FEBS Lett. 491: 85–90.
   PubMed Web of Science ®Google Scholar
• Berra, E., D. Roux, D. E. Richard, and J. Pouyssegur. 2001. Hypoxia-inducible factor-1 alpha (HIF-1α) escapes O2-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Rep. 2: 615–620.
   PubMed Web of Science ®Google Scholar
• Bird, C. H., E. J. Blink, C. E. Hirst, M. S. Buzza, P. M. Steele, J. Sun, D. A. Jans, and P. I. Bird. 2001. Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol. Cell. Biol. 21: 5396–5407.
   PubMedGoogle Scholar
• Blankenship, C., J. G. Naglich, J. M. Whaley, B. Seizinger, and N. Kley. 1999. Alternate choice of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 18: 1529–1535.
   PubMed Web of Science ®Google Scholar
• Blondel, M., J. M. Galan, Y. Chi, C. Lafourcade, Longaretti, C., R. J. Deshaies, and M. Peter. 2000. Nuclear-specific degradation of Far1 is controlled by the localization of the F-box protein Cdc4. EMBO J. 19: 6085–6097.
   PubMed Web of Science ®Google Scholar
• Bonicalzi, M. E., I. Groulx, and S. Lee. 2001. Role of exon 2-encoded β-domain of the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 276: 1407–1416.
   PubMedGoogle Scholar
• Bruick, R. K., and S. L. McKnight. 2001. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294: 1337–1340.
   PubMed Web of Science ®Google Scholar
• Chen, F., M. T. Kishida, Yao, T. Hustand, D. Glavac, M. Dean, J. R. Gnarra, M. L. Orcutt, F. M. Duh, G. Glenn, J. Green, Y. E. Hisa, J. Lamiell, H. Li, M. H. Wei, L. Schmidt, K. Tory, I. Kuzmin, T. Stackhouse, F. Latif, W. M. Linehan, M. I. Lerman, and B. Zbar. 1995. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5: 66–75.
   PubMed Web of Science ®Google Scholar
• Chen, J., J. Lin, and A. J. Levine. 1995. Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol. Med. 1: 142–152.
   PubMedGoogle Scholar
• Chen, L., M. Anton, and F. L. Graham. 1996. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell Mol. Genet. 6: 477–488.
   Google Scholar
• Cockman, M. E., N. Masson, D. R. Mole, P. Jaakkola, G. W. Chang, S. C. Clifford, E. R. Maher, C. W. Pugh, P. J. Ratcliffe, and P. H. Maxwell. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275: 25733–25741.
   PubMed Web of Science ®Google Scholar
• Davarinos, N. A., and R. S. Pollenz. 1999. Aryl hydrocarbon receptor imported into the nucleus following ligand binding is rapidly degraded via the cytosplasmic proteasome following nuclear export. J. Biol. Chem. 274: 28708–28715.
   PubMed Web of Science ®Google Scholar
• Duan, D. R., A. Pause, W. H. Burgess, T. Aso, D. Y. T. Chen, K. P. Garrett, R. C. Conaway, J. W. Conaway, W. M. Linehan, and R. D. Klausner. 1995. Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269: 1402–1406.
   PubMed Web of Science ®Google Scholar
• Duan, D. R., J. S. Humphrey, D. Y. Chen, Y. Weng, J. Sukegawa, S. Lee, J. R. Gnarra, W. M. Linehan, and R. D. Klausner. 1995. Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA 92: 6459–6463.
   PubMed Web of Science ®Google Scholar
• Epstein, A. C., J. M. Gleadle, L. A. McNeill, K. S. Hewitson, J. O'Rourke, D. R. Mole, M. Mukherji, E. Metzen, M. I. Wilson, A. Dhanda, Y. M. Tian, N. Masson, D. L. Hamilton, P. Jaakkola, R. Barstead, J. Hodgkin, P. H. Maxwell, C. W. Pugh, C. J. Schofield, and P. J. Ratcliffe. 2001. Caenorhabditis elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43–54.
   PubMed Web of Science ®Google Scholar
• Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj, and R. Luhrmann. 1995. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82: 475–483.
   PubMed Web of Science ®Google Scholar
• Foster, K., A. Prowse, A. van den Berg, S. Fleming, M. M. Hulsbeek, P. A. Crossey, F. M. Richards, P. Cairns, N. A. Affara, M. A. Ferguson-Smith, et al. 1994. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3: 2169–2173.
   PubMed Web of Science ®Google Scholar
• Freedman, D. A., and A. J. Levine. 1998. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18: 7288–7293.
   PubMed Web of Science ®Google Scholar
• Fukuchi, M., T. Imamura, T. Chiba, T. Ebisawa, M. Kawabata, K. Tanaka, and K. Miyazono. 2001. Ligand-dependent degradation of smad3 by a ubiquitin ligase complex of roc1 and associated proteins. Mol. Biol. Cell 12: 1431–1443.
   PubMed Web of Science ®Google Scholar
• Gnarra, J. R., D. R. Duan, Y. Weng, J. S. Humphrey, D. Y. Chen, S. Lee, A. Pause, C. F. Dudley, F. Latif, I. Kuzmin, L. Schmidt, F. M. Duh, T. Stackhouse, F. Chen, T. Kishida, M. H. Wei, M. I. Lerman, B. Zbar, R. D. Klausner, and W. M. Linehan. 1996. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim. Biophys. Acta 1242: 201–210.
   PubMedGoogle Scholar
• Gnarra, J. R., K. Tory, Y. Weng, L. Schmidt, M. H. Wei, H. Li, F. Latif, S. Liu, F. Chen, F. M. Duh, I. Lubensky, D. R. Duan, C. Florence, R. Pozzatti, M. M. Walther, N. H. Bander, H. B. Grossman, H. Brauch, S. Pomer, J. D. Brooks, W. B. Isaacs, M. I. Lerman, B. Zbar, and W. M. Linehan. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7: 85–90.
   PubMed Web of Science ®Google Scholar
• Gorospe, M., J. M. Egan, B. Zbar, M. Lerman, L. Geil, I. Kuzmin, and N. J. Holbrook. 1999. Protective function of von Hippel-Lindau protein against impaired protein processing in renal carcinoma cells. Mol. Cell. Biol. 19: 1289–1300.
   PubMedGoogle Scholar
• Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52: 456–467.
   PubMed Web of Science ®Google Scholar
• Groulx, I., M. E. Bonicalzi, and S. Lee. 2000. Ran-mediated nuclear export of the von Hippel-Lindau tumor suppressor protein occurs independently of its assembly with cullin-2. J. Biol. Chem. 275: 8991–9000.
   PubMed Web of Science ®Google Scholar
• Gu, Y. Z., S. M. Moran, J. B. Hogenesch, L. Wartman, and C. A. Bradfield. 1998. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3α. Gene Expr. 7: 205–213.
   PubMed Web of Science ®Google Scholar
• Hara, S., J. Hamada, C. Kobayashi, Y. Kondo, and N. Imura. 2001. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3α. Biochem. Biophys. Res. Commun. 287: 808–813.
   PubMed Web of Science ®Google Scholar
• Hershko, A., and A. Ciechanover. 1998. The ubiquitin system. Annu. Rev. Biochem. 67: 425–479.
   PubMed Web of Science ®Google Scholar
• Huang, L. E., Z. Arany, D. M. Livingston, and H. F. Bunn. 1996. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J. Biol. Chem. 271: 32253–32259.
   PubMed Web of Science ®Google Scholar
• Huang, L. E., J. Gu, M. Schau, and H. F. Bunn. 1998. Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95: 7987–7992.
   PubMed Web of Science ®Google Scholar
• Iliopoulos, O., M. Ohh, and W. G. Kaelin, Jr. 1998. pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA 95: 11661–11666.
   PubMedGoogle Scholar
• Iliopoulos, O., A. Kibel, S. Gray, and W. G. Kaelin, Jr. 1995. Tumor suppression by the human von Hippel-Lindau gene product. Nat. Med. 1: 822–826.
   PubMed Web of Science ®Google Scholar
• Ivan, M., K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J. M. Asara, W. S. Lane, and W. G. Kaelin, Jr. 2001. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464–468.
   PubMed Web of Science ®Google Scholar
• Iwai, K., K. Yamanaka, T. Kamura, N. Minato, R. C. Conaway, J. W. Conaway, R. D. Klausner, and A. Pause. 1999. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin-ligase complex. Proc. Natl. Acad. Sci. USA 96: 12436–12441.
   PubMed Web of Science ®Google Scholar
• Jaakkola, P., D. R. Mole, Y. M. Tian, M. I. Wilson, J. Gielbert, S. J. Gaskell, A. Kriegsheim, H. F. Hebestreit, M. Mukherji, C. J. Schofield, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292: 468–472.
   PubMed Web of Science ®Google Scholar
• Jewell, U. R., I. Kvietikova, A. Scheid, C. Bauer, R. H. Wenger, and M. Gassmann. 2001. Induction of HIF-1α in response to hypoxia is instantaneous. FASEB J. 15: 1312–1314.
   PubMed Web of Science ®Google Scholar
• Jones, A., C. Fujiyama, C. Blanche, J. W. Moore, S. Fuggle, D. Cranston, R. Bicknell, and A. L. Harris. 2001. Relation of vascular endothelial growth factor production to expression and regulation of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in human bladder tumors and cell lines. Clin. Cancer Res. 7: 1263–1272.
   PubMed Web of Science ®Google Scholar
• Kamura, T., D. M. Koepp, M. N. Conrad, D. Skowyra, R. J. Moreland, O. Iliopoulos, W. S. Lane, W. G. Kaelin, Jr., S. J. Elledge, R. C. Conaway, J. W. Harper, and J. W. Conaway. 1999. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science 284: 657–661.
   PubMed Web of Science ®Google Scholar
• Kamura, T., S. Sato, K. Iwai, M. Czyzyk-Krzeska, R. C. Conaway, and J. W. Conaway. 2000. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA 97: 10430–10435.
   PubMed Web of Science ®Google Scholar
• Kibel, A., O. Iliopoulos, J. A. DeCaprio, and W. G. Kaelin, Jr. 1995. Binding of the von Hippel-Lindau tumor suppressor protein to elongin B and C. Science 269: 1444–1446.
   PubMed Web of Science ®Google Scholar
• Kietzmann, T., Y. Cornesse, K. Brechtel, S. Modaressi, and K. Jungermann. 2001. Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1α, HIF2α, and HIF3α, in rat liver. Biochem. J. 354: 531–537.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10: 1054–1072.
   PubMed Web of Science ®Google Scholar
• Latif, F., K. Tory, J. Gnarra, M. Yao, F. M. Duh, M. L. Orcutt, T. Stackhouse, I. Kuzmin, W. Modi, L. Geil, L. Schmidt, F. Zhou, H. Li, M. H. Wei, F. Chen, G. Glenn, P. Choyke, M. M. Walther, Y. Weng, D. S. R. Duan, M. Dean, D. Glavac, F. M. Richards, P. A. Crossey, M. A. Ferguson-Smith, D. L. Paisler, I. Chumakov, D. Cohen, A. C. Chinault, E. R. Maher, W. M. Linehan, B. Zbar, and M. I. Lerman. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317–1320.
   PubMed Web of Science ®Google Scholar
• Lee, S., D. Y. T. Chen, J. S. Humphery, J. R. Gnarra, W. M. Linehan, and R. D. Klausner. 1996. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc. Natl. Acad. Sci. USA 93: 1770–1775.
   PubMedGoogle Scholar
• Lee, S., M. Neumann, R. Stearman, R. Stauber, A. Pause, G. N. Pavlakis, and R. D. Klausner. 1999. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Mol. Cell. Biol. 19: 1486–1497.
   PubMed Web of Science ®Google Scholar
• Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
   PubMed Web of Science ®Google Scholar
• Linehan, W. M., M. I. Lerman, and B. Zbar. 1995. Identification of the von Hippel-Lindau (VHL) gene: its role in renal cancer. JAMA 273: 564–570.
   PubMed Web of Science ®Google Scholar
• Lisztwan, J., G. Imbert, C. Wirbelauer, M. Gstaiger, and W. Krek. 1999. The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev. 13: 1822–1833.
   PubMed Web of Science ®Google Scholar
• Lonergan, K. M., O. Iliopoulos, M. Ohh, T. Kamura, R. C. Conaway, J. W. Conaway, and W. G. Kaelin., Jr. 1998. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18: 732–741.
   PubMed Web of Science ®Google Scholar
• Masson, N., C. Willam, P. H. Maxwell, C. W. Pugh, and P. J. Ratcliffe. 2001. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J. 20: 5197–5206.
   PubMed Web of Science ®Google Scholar
• Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275.
   PubMed Web of Science ®Google Scholar
• Momand, J., G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine. 1992. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237–1245.
   PubMed Web of Science ®Google Scholar
• Ohh, M., C. W. Park, M. Ivan, M. A. Hoffman, T. Y. Kim, L. E. Huang, N. Pavletich, V. Chau, and W. G. Kaelin. 2000. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2: 423–427.
   PubMed Web of Science ®Google Scholar
• Oliner, J. D., J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362: 857–860.
   PubMed Web of Science ®Google Scholar
• Pause, A., S. Lee, R. A. Worrell, D. Y. Chen, W. H. Burgess, W. M. Linehan, and R. D. Klausner. 1997. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA 94: 2156–2161.
   PubMed Web of Science ®Google Scholar
• Pause, A., B. Peterson, G. Schaffar, R. Stearman, and R. D. Klausner. 1999. Studying interactions of four proteins in the yeast two-hybrid system: structural resemblance of the pVHL/elongin BC/hCUL-2 complex with the ubiquitin ligase complex SKP1/cullin/F-box protein. Proc. Natl. Acad. Sci. USA 96: 9533–9538.
   PubMed Web of Science ®Google Scholar
• Roth, J., M. Dobbelstein, D. A. Freedman, T. Shenk, and A. J. Levine. 1998. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J. 17: 554–564.
   PubMed Web of Science ®Google Scholar
• Ryan, H. E., M. Poloni, W. McNulty, D. Elson, M. Gassmann, J. M. Arbeit, and R. S. Johnson. 2000. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth. Cancer Res. 60: 4010–4015.
   PubMed Web of Science ®Google Scholar
• Salceda, S., and J. Caro. 1997. Hypoxia-inducible factor 1α (HIF-1α) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272: 22642–22647.
   PubMed Web of Science ®Google Scholar
• Scheffner, M. 1999. Moving protein heads for breakdown. Nature 398: 103–104.
   PubMed Web of Science ®Google Scholar
• Schoenfeld, A., E. J. Davidowitz, and R. D. Burk. 1998. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA 95: 8817–8822.
   PubMed Web of Science ®Google Scholar
• Semenza, G. L. 2000. HIF-1 and human disease: one highly involved factor. Genes Dev. 14: 1983–1991.
   PubMed Web of Science ®Google Scholar
• Stauber, R., G. A. Gaitanaris, and G. N. Pavlakis. 1995. Analysis of trafficking of Rev and transdominant Rev proteins in living cells using green fluorescent protein fusions: transdominant Rev blocks the export of Rev from the nucleus to the cytoplasm. Virology 213: 439–449.
   PubMedGoogle Scholar
• Stebbins, C. E., W. G. Kaelin, Jr., and N. P. Pavletich. 1999. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455–461.
   PubMed Web of Science ®Google Scholar
• Tanimoto, K., Y. Makino, T. Pereira, and L. Poellinger. 2000. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19: 4298–4309.
   PubMed Web of Science ®Google Scholar
• Tomoda, K., Y. Kubota, and J. Kato. 1999. Degradation of the cyclin-dependent-kinase inhibitor p27Kip1 is instigated by Jab1. Nature 398: 160–165.
   PubMed Web of Science ®Google Scholar
• Xirodimas, D. S., C. W. Stephen, and D. P. Lane. 2001. Compartmentalization of p53 and Mdm2-mediated degradation of p53. Exp. Cell Res. 270: 66–77.
   PubMedGoogle Scholar
• Yu, F., S. B. White, Q. Zhao, and F. S. Lee. 2001. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation Proc. Natl. Acad. Sci. USA 98: 9630–9635.
   PubMed Web of Science ®Google Scholar